Physician profile
Taimur Akram
NPI 1902034804
$7,009.44
in general payments reported to CMS, 2019-2025
31 companies · $789 in 2025
The $789 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,513 · 2020: $451 · 2021: $875 · 2022: $662 · 2023: $1,302 · 2024: $1,418 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,508 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,508.32 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,968.01 | 2019-2025 | |
| Pfizer INC. | $470.94 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $420.63 | 2019-2024 | Zeposia, Eliquis |
| Novo Nordisk INC | $389.22 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Sk Life Science, INC. | $325.90 | 2020-2024 | Xcopri |
| Biogen, INC. | $307.05 | 2021-2024 | Vumerity, Tysabri |
| Biohaven Pharmaceuticals, INC. | $289.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $259.59 | 2019-2020 | |
| Glaxosmithkline, LLC. | $245.56 | 2019-2023 | Trelegy Ellipta |
| Neurelis, INC. | $225.00 | 2022-2023 | Valtoco |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.00 | 2023-2025 | Xifaxan, Trulance |
| Genentech USA, INC. | $177.26 | 2021-2023 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $157.84 | 2019 | |
| Abbvie INC. | $148.85 | 2024 | |
| Celgene Corporation | $134.66 | 2023 | Zeposia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $130.64 | 2019 | |
| Amgen INC. | $125.01 | 2024 | |
| Argenx US, INC. | $125.00 | 2025 | Vyvgart |
| Lilly USA, LLC | $121.06 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $117.55 | 2019-2022 | |
| Genentech, INC. | $108.99 | 2024 | Ocrevus, Enspryng |
| Ucb, INC. | $101.76 | 2025 | Briviact |
| Jazz Pharmaceuticals INC. | $101.76 | 2024 | |
| Emd Serono, INC. | $93.98 | 2020 | |
| Adamas Pharmaceuticals, INC. | $51.69 | 2019 | |
| Greenwich Biosciences, INC. | $51.04 | 2021 | |
| Neurocrine Biosciences, INC. | $50.65 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.80 | 2022 | |
| Beigene USA, INC. | $49.02 | 2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $16.07 | 2023 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taimur Akram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.